Lead Product(s) : OT-C001,Rituximab
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : EMERCell
Deal Size : Inapplicable
Deal Type : Inapplicable
Onward Therapeutics gets IMPD OK to Start Allogeneic NK Cell Study
Details : OT-C001 is an optimized cell therapy product consisting of highly activated & allogeneic NK cells. It is being evaluated for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
Product Name : OT-C001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 21, 2025
Lead Product(s) : OT-C001,Rituximab
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : EMERCell
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ALE.P02
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : OrbiMed Advisors
Deal Size : $181.4 million
Deal Type : Series D Financing
Alentis Raises $181.4M To Advance Anti-Claudin-1 ADCs in Solid Tumors
Details : The financing will support the development of first-in-class CLDN1 targeted medicines including Phase 1/2 studies of ALE.P02 and ALE.P03, first-in-class ADCs designed by linking a potent cancer drug.
Product Name : ALE.P02
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
December 11, 2024
Lead Product(s) : ALE.P02
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : OrbiMed Advisors
Deal Size : $181.4 million
Deal Type : Series D Financing
Lead Product(s) : ALE.P02
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alentis Gains FDA Fast Track for ALE.P02 in CLDN1+ Squamous Solid Tumors
Details : ALE.P02 is a first-in-class ADC designed by linking a tubulin inhibitor, a potent cancer drug. It is being evaluated for the treatment of CLDN1+ squamous cancers.
Product Name : ALE.P02
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
November 18, 2024
Lead Product(s) : ALE.P02
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BPT567
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Johnson & Johnson
Deal Size : $90.0 million
Deal Type : Series C Financing
Bright Peak Therapeutics Announces $90 Million in Series C Financing for PD1-IL18
Details : The proceeds from the Series C financing will be used to advance the Bright Peak Therapeutics lead product BPT567 into a clinical trial for the treatment of neoplasms.
Product Name : BPT567
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
November 06, 2024
Lead Product(s) : BPT567
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Johnson & Johnson
Deal Size : $90.0 million
Deal Type : Series C Financing
Lead Product(s) : ANV600,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
Details : Anaveon investigational product ANV600 monotherapy and combination with Keytruda as part of a multi-cohort study to evaluate the safety and efficacy of ANV600 in multiple cancer indications.
Product Name : ANV600
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
May 29, 2024
Lead Product(s) : ANV600,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ALE.P02
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alentis Therapeutics Receives FDA IND Clearance For ALE.P02 For Squamous Cancers
Details : ALE.P02 is a first-in-class ADC designed by linking a tubulin inhibitor, a potent cancer drug. It is being evaluated for the treatment of squamous cancers.
Product Name : ALE.P02
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
February 10, 2024
Lead Product(s) : ALE.P02
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CDR404
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CDR-Life Receives FDA Clearance for IND of CDR404 for Solid Tumor Treatment
Details : CDR404 is a bispecific MAGE-A4 T-cell engager based on M-gager® technology, currently in preclinical studies for lung, bladder, and esophageal cancers.
Product Name : CDR404
Product Type : Antibody
Upfront Cash : Inapplicable
January 23, 2024
Lead Product(s) : CDR404
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ALE.C04
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ALE.C04 is a first-in-class monoclonal antibody developed to specifically target exposed CLDN1 on cancer cells. This investigational antibody is designed to treat patients with recurrent or metastatic, CLDN1-positive HNSCC.
Product Name : ALE.C04
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
August 24, 2023
Lead Product(s) : ALE.C04
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NPX887
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NextPoint investigational product NPX887 is a fully human monoclonal antibody targeting HHLA2 (B7-H7). Currently evaluating under the IND enabling stage for the treatment of solid tumors known to express HHLA2, a tumor antigen strongly upregulated in man...
Product Name : NPX887
Product Type : Antibody
Upfront Cash : Inapplicable
July 12, 2023
Lead Product(s) : NPX887
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IOS-1002
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ImmunOs Therapeutics Receives Regulatory Approval for First-In-Human Trial of IOS-1002
Details : IOS-1002 is a first-in-class, multi-functional agent based on a naturally occurring human leukocyte antigen (HLA) that targets multiple immune checkpoints to activate both innate and adaptive immune cells, thereby leading to profound anti-tumor activity.
Product Name : IOS-1002
Product Type : Protein
Upfront Cash : Inapplicable
January 17, 2023
Lead Product(s) : IOS-1002
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable